Targeting CGRP: A new approach to migraine care
Headache disorders, one of the most common being migraine, were the second most disabling impairments worldwide in 2017.1 As strides in migraine pathophysiology were made to address such a prevalent disease, new classes of migraine medication have been developed over the last three decades.2 Relevant to this progress is calcitonin gene related peptide (CGRP), a neuroi
Login to register to read this article
If you do not have a Log in, please register to be part of a big community, experience premium content and stay informed about exclusive professional events.
Log InNot registered yet? Register now